Over the past decades, it has become increasingly accepted that the risk of cardiovascular (CV) morbidity and mortality is noticeably augmented in rheumatoid arthritis (RA) patients [1]. When compared to the general population, the mere existence of said condition increases CV death risk by up to 50% [2]. Furthermore, more than half of premature mortality in these patients is attributable to CV disease, which remains as their leading cause of death [2–4]. Therefore, RA, by itself, is now accepted as an independent cardiovascular risk factor, due to its inherent chronic and systemic pro-inflammatory state [1].
